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ABSTRACT:
Expression of the long noncoding RNA (lncRNA) SPRY4-IT1 is low in normal
human melanocytes but high in melanoma cells. siRNA knockdown of SPRY4IT1 blocks melanoma cell invasion and proliferation, and increases apoptosis. To
investigate its function further, we affinity purified SPRY4-IT1 from melanoma
cells and used mass spectrometry to identify the protein lipin 2, an enzyme that
converts phosphatidate to diacylglycerol (DAG), as a major binding partner. SPRY4IT1 knockdown increases the accumulation of lipin2 protein and upregulate the
expression of diacylglycerol O-acyltransferase 2 (DGAT2) an enzyme involved in
the conversion of DAG to triacylglycerol (TAG). When SPRY4-IT1 knockdown and
control melanoma cells were subjected to shotgun lipidomics, an MS-based assay that
permits the quantification of changes in the cellular lipid profile, we found that SPRY4IT1 knockdown induced significant changes in a number of lipid species, including
increased acyl carnitine, fatty acyl chains, and triacylglycerol (TAG). Together, these
results suggest the possibility that SPRY4-IT1 knockdown may induce apoptosis via
lipin 2-mediated alterations in lipid metabolism leading to cellular lipotoxicity.

INTRODUCTION

LncRNAs may be derived from genomic sequences that
are intergenic, intronic, overlapping, or antisense with
respect to nearby protein-coding genes, and although some
lncRNAs may be translated into short polypeptides, the
vast majority are rarely or never translated [7, 8].
Until recently, lncRNAs were frequently dismissed
as non-functional transcriptional ‘‘noise’’ [9]. However,
the past few years have seen a rapid increase in our
understanding of the regulatory functions of lncRNAs
and their role in human disease and development [10,
11]. LncRNAs exhibit exquisite context-dependency
commensurate with their presumed regulatory role, with
cell type-specific expression and localization to discrete
subcellular compartments [12-14]. At the molecular level,

Eukaryotic genomes express a complex repertoire
of thousands of RNAs that lack protein-coding capacity
[1, 2]. These noncoding RNAs (ncRNAs) are broadly
classified as long or small based on a nucleotide length
of >200 or <200 nucleotides (nt), respectively. Small
regulatory ncRNAs are commonly conserved and are
involved in transcriptional and posttranscriptional gene
regulation through specific base pairing with their target
genes or transcripts. In contrast, long noncoding RNAs
(lncRNAs) are less well conserved and regulate gene
expression by diverse mechanisms, including epigenetic
mechanisms, that remain incompletely understood [3-6].
www.impactjournals.com/oncotarget
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lncRNAs influence target gene expression at specific
genomic loci by directly interacting with chromatin
regulatory proteins and/or by modulating the activity
of their interacting partners [15-20]. LncRNAs can
function as decoys for bound proteins and can also alter
the structure and function of the protein [17]. Although
lncRNAs play physiological roles during normal cellular
development and differentiation [21], changes in their
expression are associated with several diseases, including
cancer, heart disease, Alzheimer’s disease, psoriasis,
and spinocerebellar ataxia type 8 [22]. Accumulating
evidence suggests that lncRNAs may also play a role
in tumorigenesis. For example, increased expression of
HOTAIR is associated with poor prognosis in pancreatic
cancer [23], and increased expression of PCGEM1 and
PCA3/DD3 is associated with a high risk of developing
prostate cancer [24].
Recently, we identified a number of lncRNAs that
are differentially expressed in melanoma cell lines relative
to melanocytes and keratinocytes [14, 25]. One of these,
SPRY4-IT1 (Sprouty4-Intron 1; GenBank accession
ID AK024556), is highly expressed in melanoma cells
relative to melanocytes, and is localized predominantly in
the cytoplasm. Previously we showed that SPRY4-IT1 is
derived from the intronic region of the SPRY4 gene and
that its predicted secondary structure contains several long
hairpins [14]. Moreover, RNAi-mediated knockdown of
SPRY4-IT1 inhibited invasion and proliferation and
induced apoptosis of melanoma cells, suggesting an
important role for this lncRNA in melanoma biology.
In the present study, we sought to identify SPRY4IT1-interacting proteins and elucidate this lncRNA’s
molecular function. In melanoma cells, SPRY4-IT1
transcripts are processed in the nucleus prior to transport
to the cytoplasm, where they are primarily located in
polysomes. We also identify the phosphatidate lipin 2 as
a major SPRY4-IT1-binding protein, and demonstrate the
existence of a novel lipid regulatory mechanism involving
SPRY4-IT1 and lipin 2. Our results are consistent with
the possibility that SPRY4-IT1 knockdown may induce
apoptosis via lipin 2-mediated alterations in lipid
metabolism leading to cellular lipotoxicity. Together these
results provide novel insight into the mechanisms by
which extranuclear processing of lncRNAs contributes to
melanoma biology.

and extend to exon 3 (Fig. 1A). Interestingly, the 5′ region
of the full-length SPRY4-IT1 transcript was detected in
samples of nuclear, but not cytoplasmic RNA, suggesting
that the processing of SPRY4-IT1 takes place before
nucleocytoplasmic export (Fig. 1B). We confirmed using
5′ RACE that the first 244 nt of the 5′ sequence is missing
from cytoplasmic SPRY4-IT1 (Fig. S1). To validate this
observation and to visualize the subcellular localization
of SPRY4-IT1, we designed several RNA-FISH probes
specific for the 3′ or 5′ regions of SPRY4-IT1. This analysis
confirmed the presence of the full-length transcript in the
nucleus but not in the cytoplasm (Fig. S2), in agreement
with PCR results. SPRY4-IT1 staining in melanocytes is
mainly localized to the nucleus and this may be the reason
of intense nuclear staining in melanocytes. Together
these data demonstrate that the SPRY4-IT1 transcript
undergoes maturation by cleavage of the 5’ region prior
to its transport to the cytoplasm. This may suggest that
the regulation of the 5’ cleavage controls the export of
the transcript to the cytoplasm thus, the overall SPRY4IT1 content may depend on the efficiency of the nuclear
excision event.
Although the precise 3′ termination site of the
SPRY4-IT1 transcript is not yet known, northern
blot analysis shows a SPRY4-IT1 transcript size of
approximately 1.8 kb (Fig. 1C), and the 3′ sequence of the
transcript is very similar to that of Exon 3 of the SPRY4
gene. Therefore, we propose that SPRY4-IT1 carries both
intronic and exonic sequences and can be considered a
noncoding splice variant of the SPRY4 gene.

SPRY4-IT1 and SPRY4 Gene Transcripts
Function Independently
We next asked whether the transcription and
function of SPRY4-IT1 and SPRY4 are coordinately or
independently regulated. Despite the similar expression
patterns of SPRY4 and SPRY4-IT1, siRNA-mediated
knockdown of SPRY4 (siRNA targeting exon 1) in A375
melanoma cells reduced the expression of SPRY4 but not
SPRY4-IT1 (Fig. 1D), demonstrating that transcription
of the coding (SPRY4) and noncoding (SPRY4-IT1)
genes occurred independently. To confirm this in a more
physiological setting, we treated melanocytes (low
expression of SPRY4-IT1) with fibroblast growth factor 2
(FGF2), which is known to induce SPRY4 expression [27].
In serum-containing medium, FGF2 induced expression
of SPRY4-IT1 and SPRY4 to similar extents (Fig. 2A).
However, SPRY4-IT1 transcription was further elevated
in melanocytes treated with FGF2 in serum-free medium
(Fig. 2B), confirming independent transcription of SPRY4IT1 and SPRY4. These results suggest that SPRY4-IT1
responds to starvation and general stress responses.
To determine whether the stability of SPRY4-IT1 and
SPRY4 transcripts is independently regulated, we treated

RESULTS
Processing of SPRY4-IT1 Transcripts
SPRY4-IT1 was originally identified as a 706 bp
transcript in adipose tissue as part of a large-scale cDNA
sequencing study [26]. The SPRY4-IT1 sequence was
shown by PCR to initiate in intron 1 of the SPRY4 gene
www.impactjournals.com/oncotarget
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Figure 1:Maturation and Cellular Compartmentalization of SPRY4-IT1 Transcripts. (A) The sequence and location of

SPRY4 and SPRY4-IT1. SPRY4-IT1 is embedded in the SPRY4 parent transcript. SPRY4-IT1 starts in the first intron of the SPRY4 gene and
extends up to exon 3. 5′ RACE shows the maturation and cleavage of a 244 nt transcript in the 5′ region of SPRY4-IT1. (B) Detection of
nuclear and cytoplasmic forms of SPRY4-IT1. (C) Northern blot analysis shows the sizes of SPRY4 (4.9 kb) and SPRY4-IT1 (1.8 kb). The
SPRY4 exon 1 probe hybridizes specifically to SPRY4, but the SPRY4 exon 3 probes recognize both SPRY4 and SPRY4-IT. (D) SPRY4 exon
1 siRNA knocks down the expression of SPRY4, but not SPRY4-IT1, in A375 melanoma cells.
www.impactjournals.com/oncotarget
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SPRY4-IT1 Is Localized to the Polysome Fraction
and Binds the Lipid Phosphatase Lipin 2

A375 cells with the polymerase II transcriptional inhibitor
α-amanitin and measured the transcript levels by RTPCR. We observed that SPRY4 RNA decayed faster than
SPRY4-IT1 in both the nucleus and cytoplasm, supporting
the functional independence of the transcripts (Fig. S3).
Finally, we independently knocked down SPRY4 and
SPRY4-IT1 in A375 cells using transcript-specific siRNAs.
Confirming our previous report [14], A375 cell invasion
was inhibited ~50% by SPRY4-IT1 knockdown but was
unaffected by SPRY4 silencing (Fig. S4A). Similarly,
SPRY4-IT1 silencing induced apoptosis of A375, as
measured by caspase 3 activity, more effectively than did
SPRY4 knockdown (Fig. S4B). Collectively, these data
establish the transcriptional and functional independence
of SPRY4-IT1 and its host gene SPRY4.

In a recent ribosomal footprint study, Ingolia et al.
[28] reported that cytoplasmic lncRNAs are primarily
found in ribosomal clusters or polysomes. To determine
the location of SPRY4-IT1, we used density gradient
centrifugation to isolate monosomal and polysomal
fractions from A375 cells and recovered 13 fractions:
2 monosomal and 11 polysomal (Fig. 3A). Total RNA
was isolated from the individual fractions and analyzed
for the presence of SPRY4-IT1 by northern blotting.
SPRY4-IT1 was detected only in polysomal fractions
3 through 9 (Fig. 3B), indicating that SPRY4-IT1 is
indeed associated with polysomes and is not retained in
monosomes, consistent with the findings of Ingolia et al.
[28]. Sequence analysis further confirmed that SPRY4-IT1

Figure 2: SPRY4 and SPRY4-IT1 Are Coordinately Regulated in Melanocytes. Relative expression of SPRY4-IT1 and SPRY4
following induction by FGF2. Melanocytes were treated with 10 ng/ml FGF2 for 1 or 2 h in the presence or absence of FBS, and the fold
change in expression of SPRY4 (A) and SPRY4-IT1 (B) was measured by qPCR
www.impactjournals.com/oncotarget
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loss of SPRY4-IT1 (Fig. 4C). This result suggests that
the loss of lipin 2 most likely destabilizes SPRY4-IT1. In
contrast, knockdown of SPRY4-IT1 increased both lipin
2 mRNA and protein by ~2.5-fold (Fig. 4D and 4F). PAP
enzymatic activity was markedly increased in SPRY4IT1 knockdown cells (Fig. 4E). Given that SPRY4-IT1
knockdown had no effect on lipin 1 expression (Fig. S5),
these data suggest that the increased PAP activity in these
cells is due to the increased abundance of lipin 2. It is
worth noting that knockdown of the SPRY4 gene did not
affect the expression of either SPRY4-IT1 or lipin 2 (Fig.
4).

does not show any coding potential; understanding its role
in possible translational regulation is an ongoing study in
our laboratory.
We next sought to identify SPRY4-IT1-binding
proteins in melanoma cells. For this, we affinity purified
endogenous SPRY4-IT1 from crosslinked A375 lysate
(Fig. 4A) and interrogated the SPRY4-IT1-associated
proteins by mass spectrometry (MS). A group of candidate
proteins was identified and quantified by spectral counting
(Table S1). The most abundant protein candidate was
lipin 2 [29], a phosphatidic acid phosphatase (PAP) that
converts phosphatidate into diacylglycerol (DAG). Lipin
2 was pulled down specifically with SPRY4-IT1 but not
with scrambled (control) probes. To verify the physical
association between lipin 2 and SPRY4-IT1, lipin 2 was
immunoprecipitated, and associated RNAs were isolated
and interrogated for the presence of SPRY4-IT1 by qPCR.
As shown in Figure 4B, SPRY4-IT1 transcripts were
enriched in anti-lipin 2 immunoprecipitated compared
with control IgG.
We next investigated the functional significance
of the association between SPRY4-IT1 and lipin 2 in
melanoma cells using gene-specific RNAi. Knockdown of
lipin 2 with two independent siRNAs led to a concurrent

SPRY4-IT1 Knockdown Increases Triacylglycerol
Production via Lipin 2
To investigate the effect of SPRY4-IT1 modulation of
lipin 2 expression on global lipid metabolism in melanoma
cells, we subjected SPRY4-IT1 knockdown and control
A375 cells to shotgun lipidomics, an MS-based assay that
permits the quantification of changes in the cellular lipid
profile (Table S2). We found that SPRY4-IT1 knockdown
induced significant changes in a number of lipid species,

Figure 3: SPRY4-IT1 Accumulates in Polysomes and Is Absent from Monosomes. (A) Density gradient fractionation of

monosome and polysome peaks. (B) Northern blot analysis showing SPRY4-IT1 probe hybridization to RNA isolated from polysomes but
not monosomes. A GAPDH probe served as a control. Separate blots were prepared to probe SPRY4-IT1 and control (GAPDH) due to
concerns of overlap in fragment size. L= RNA size marker.
www.impactjournals.com/oncotarget

8963

Oncotarget

including increased acyl carnitines (+80.21%), fatty acyl
chains (+14.24%), and triacylglycerol (TAG) (+15.02%),
as well as decreased phosphatidic acid (-37.72%),
phosphatidylcholine (-35.58%), phosphatidylinositol
(-27.78%),
and
phosphatidylserine
(-26.40%).
Interestingly, DAG content was decreased despite the
increase in TAG levels. Since DAG is required for
TAG synthesis, we hypothesized that the reduction in
DAG levels in SPRY4-IT1 knockdown cells may be due
to efficient conversion of DAG to TAG. To test this,
we examined the expression of acyl-CoA:glycerol-3phosphate acyltransferase 3 (GPAT3), diacylglycerol

O-acyltransferase 1 (DGAT1), and diacylglycerol
O-acyltransferase 2 (DGAT2), since these enzymes
play essential roles in DAG to TAG conversion. qPCR
analysis showed that both DGAT2 and GPAT3 mRNA
levels were increased in SPRY4-IT1 knockdown cells
(Fig. 5), providing a possible mechanism for the changes
in DAG and TAG levels in these cells. We postulate that
one mechanism by which SPRY4-IT1 knockdown induces
apoptosis could be through lipin 2-mediated lipotoxicity.
To investigate further, we knocked-down and overexpressed lipin 2 in A375 cells and measured cell invasion
efficiency and doubling time. Interestingly, we observed

Figure 4:SPRY4-IT1 Knockdown Increases Lipin 2 Protein Accumulation in Melanoma Cells. A) Affinity purification

of SPRY4-IT1 from A375 cell lysates with SPRY4-IT1-specific probes followed by qPCR. SPRY4-IT1 is enriched compared to scrambled
(control) probes. U1 RNA was used as endogenous control for pull-downs. (B) qPCR validation showing enrichment of SPRY4-IT1
following immunoprecipitation of A375 cell lysates with lipin 2-specific or control IgG antibodies. (C) Relative expression of SPRY4-IT1
in lipin 2 knock-down cells (D) Relative expression of lipin 2 after siRNA-mediated knockdown of SPRY4-IT1, SPRY4 exon 1 or lipin 2.
(E) Phosphatidic acid phosphatase assay. (F) Western blot analysis of lipin 2 following siRNA-mediated knockdown of SPRY4-IT1 or lipin
2. All experiments were performed in triplicate.
www.impactjournals.com/oncotarget
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molecular function of SPRY4-IT1 and elucidating its
possible molecular function in melanomas.
We found that SPRY4-IT1 is part of a longer
noncoding transcript that is processed by cleavage of a
244 nt 5′ fragment prior to transport to the cytoplasm. The
fate of the 244 nt fragment is unknown, but it is likely to
be degraded by exo- and endonucleases. The maturation
of SPRY4-IT1 is similar to the nuclear processing of
MALAT1 in lung cancer [30]. We also showed that SPRY4
and SPRY4-IT1 are independent transcripts, although they
may be regulated by the same transcriptional machinery.
A recent study classifying lncRNAs according to their
genomic origin showed they may originate from (a)
a bidirectional promoter adjacent to a protein-coding
gene, (b) the 5′ UTR, (c) a retained intron, (d) within
an intron, (e) the 3′ UTR, (f) an intergenic non-proteincoding region, (g) antisense to protein-coding genes, or
(f) a combination of the above [31]. According to this
classification, SPRY4-IT1 therefore belongs to the group
of intron-retained lncRNAs.
One of the direct targets of SPRY4-IT1 identified
in this study is lipin 2, a member of the lipin family
of phosphatidate phosphatase enzymes [32]. The
mouse lipin 2 protein has previously been shown to
be post-transcriptionally regulated [33]. We showed
that knockdown of SPRY4-IT1 modulates cellular
concentrations of lipin 2 substrates, including
phosphatidate, and cells expressing high SPRY4-IT1
levels, such as melanomas, might thus be expected to
accumulate lipin 2 substrates. Indeed, increased levels of
phosphatidate have been linked to certain types of cancers
through allosteric activation of the molecular target of
rapamycin (mTOR) [34] and to a possible role for lipin
2 in statin resistance of colorectal carcinoma cells in
vitro [35]. It would be of interest to determine whether
the influence of SPRY4-IT1 on melanocyte and melanoma
proliferation involves inhibition of lipin 2 activity and/or
activation of mTOR.
Our results are the first to demonstrate a role for
a lncRNA in lipid metabolism in melanoma cells, and
collectively, the data support the notion that SPRY4-IT1
may play a critical role in melanocytic transformation.

that cell doubling time was increased and cell invasion
was decreased in both knock-down and force-expressed
cells (Fig. S6A and B). We postulate that lipin 2 levels
must be maintained on a steady state level in melanoma
cells, and modulating lipin 2 levels (either an increase
or decrease) can negatively affect cell physiology. For
comparison, we subjected the primary melanocyte cell
line HEM-l to shotgun lipidomics, and compared cellular
lipid profiles to A375 cells. Interestingly, we found that
lipid levels were significantly different in these two
cell types. For an example, phosphatidylethanolamine
(PE), Phosphatidylserine (PS), Phosphatidic acid (PA),
Sphingomyelin (SM) were higher in melanocytes,
compared to melanoma cells (Table S3). Studying the
role of lipids in melanocyte and melanoma biology is an
ongoing study in our laboratory.

DISCUSSION
In contrast to small ncRNAs, which are highly
conserved and play a role in transcriptional and
posttranscriptional gene silencing through specific base
pairing, lncRNAs are often poorly conserved (perhaps
reflecting lineage specificity and/or more plastic structure–
function constraints) and regulate gene expression by
diverse mechanisms that are not yet fully understood. We
previously identified the lncRNA SPRY4-IT1, which is
derived from the intronic region of the Sprouty4 gene, and
is upregulated in human melanomas compared to normal
melanocytes and keratinocytes [14]. siRNA-mediated
knockdown of SPRY4-IT1 in melanoma was shown to
affect cell proliferation and apoptosis, suggesting that
high SPRY4-IT1 expression may play an important role
in the molecular etiology of human melanomas. In this
study, we sought to probe this further by identifying the

MATERIAL AND METHODS
Cell Lines
Human epidermal melanocytes (HEM-l) were
grown in MelM media containing MelGS growth
supplements, 0.5% fetal bovine serum (FBS), penicillin,
and streptomycin. Melanoma cells A375 (stage 4) were
grown in Complete Tu medium containing a 4:1 mixture of
MCDB-153 medium with 1.5 mg/ml sodium bicarbonate
and Leibovitz’s L-15 medium with 2 mM L-glutamine,

Figure
5:
Expression
of
Diacylglycerol
O-acyltransferase 2 and (DGAT2) Acyl-coA:glycerol3-phosphate Acyltransferase 3 (GPAT3) Following
SPRY4-IT1 Knockdown. Both DGAT2 (A) and GPAT3 (B)
mRNA levels are increased upon knockdown of SPRY4-IT1 in
A375 cells, which may explain the decrease in DAG levels and
increase in TAG levels observed in these cells (Table S2).
www.impactjournals.com/oncotarget
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2% FBS, and 1.68 mM CaCl2. Cells were grown at 37°C
in a humidified 5% CO2 atmosphere. All cell lines were
obtained from ATCC (http://www.atcc.org).

BD BioCoat™ Matrigel™ Invasion Chambers
(24-well plates) were prepared by rehydrating the
BD Matrigel™ matrix coating with 0.5 ml of serumfree Complete Tu medium for 2 h at 37°C in a 5%
CO2 atmosphere. After rehydration, the solution was
removed and 0.5 ml of Complete Tu medium containing
chemoattractant (2% FBS) was added to the lower wells,
and 0.5 ml of serum-free Complete Tu medium containing
5 × 104 A375 cells transfected with siRNAs was added
to the insert wells. Invasion assay plates were incubated
for 2 days at 37°C in a humidified 5% CO2 atmosphere.
Non-invading cells were removed by scrubbing the upper
surface of the insert, and invading cells on the lower
surface of the insert were stained with crystal violet.
Each membrane was mounted on a microscope slide for
visualization and analysis. Slides were scanned using a
Scanscope digital slide scanner, and the migrated cells
were enumerated using Aperio software. All experiments
were performed with biological triplicates.

Cloning and Identification of 3′ Spliced Forms of
SPRY4-IT1
Total RNA was isolated from A375 cells with
TRIzol (Invitrogen) and reversed transcribed using
M-MLV reverse transcriptase. The cDNA was used as a
template for PCR amplification with various 5′ primers
within SPRY4-IT1 and 3′ primers downstream in the
SPRY4 locus. Successful amplification was achieved with
two forward primers: 5′ IT1 (gtagagatgggggtttcatcctgttg),
which anneals to the first base of SPRY4-IT1, and SPRY4IT1 qPCR (gctgagctggtggttgaaaggaatc), which is located
305 bp within the SPRY4-IT1 sequence. Successful
amplification at the 3′ end was achieved with the reverse
primer SPRY4 Exon 3 (gtccgctttgggccggtgg), which is
located 229 bp into the third exon of SPRY4. Amplification
was unsuccessful using primers 500 bp downstream of
this location. PCR products were cloned and sequenced.
Sequences were aligned to the genomic template and
verified using Vector NTi Advance and AlignX.

Apoptosis Assay
A375 cells were trypsinized and reverse transfected
with siRNAs as described above. Caspase activity was
measured using the Caspase-Glo® 3/7 Assay kit (Promega)
according to the manufacturer’s recommendations, and
samples were read on a GloMax luminometer (Promega).

Northern Blot Analysis
Total RNA was isolated from each cell line with
TRIzol and concentrated. Aliquots of RNA (20 μg
per sample) were mixed with equal volumes of 2×
NorthernMax-Gly Loading Dye (with ethidium bromide),
heated at 50°C for 30 min, and resolved on a 1% glyoxal
agarose gel run at 65 V for 2 h 20 min in 1× running
buffer. The gel was transferred to a nylon membrane
(BrightStar Plus, Ambion) using downward capillary
transfer, crosslinked using a UVP UV crosslinker at
1200 (UVP HL-2000 HybriLinker), prehybridized for
30 min at 42°C in 6 ml ULTRAhyb (Ambion), and then
probed overnight at 42°C. Blots were processed with the
BrightStar BioDetect kit (Ambion) and exposed to film.
The following biotin-labeled DNA probes (IDT) were
used at 166 nM: SPRY4-IT1, ctccactgggcatattctaaaa;
SPRY4 Exon 1, gatgttgcaaccactgcctgg; SPRY4
Exon 3, catggctggtcttcacctggtc; and GAPDH,
gggccatgaggtccaccaccc.

Polysome Fractionation
Cells grown in 10 cm dishes were gently removed
with PBS and collected by centrifugation for 4 min at 100
× g. The cell pellet was resuspended in 500 μl of lysis
buffer (100 mM KCl, 50 mM Tris-HCl pH 7.4, 1.5 mM
MgCl2, 1 mM dithiothreitol (DTT), 1 mg/ml heparin,
1.5% NP-40, 100 μM cycloheximide, 1% aprotinin, 1 mM
AEBSF, and 100U/ml of RNasin) and incubated on ice
for 15 min. The lysate was centrifuged at 1000 × g and
the infranatant lysate was removed from underneath the
“fat cake”. The nuclei were pelleted by centrifugation
in a microfuge for 10 min at 12,000 rpm. The resulting
supernatant was carefully removed and applied to the top
of a 15–60% sucrose gradient (in 100 mM KCl, 5 mM
MgCl2, 20 mM HEPES pH 7.4, and 2 mM DTT). The
gradients were centrifuged at 35,000 rpm for 3.5 h at 4°C
in a Beckman SW41 rotor. Samples containing (i) free
(unbound) mRNA, ribosomal subunits, and monosomes,
and (ii) polysomes were recovered from the gradients
using a Brandel density gradient fractionator equipped
with an ISCO UA-6 flow cell set to 254 nm (a 70%
sucrose solution containing orange G was slowly pumped
into the bottom of the tube to displace the contents from
top to bottom). Fractions were collected directly into an
equal volume of TRIzol for isolation of RNA. The purity
and integrity of RNA was determined with an Agilent

Invasion Assay
A375 cells were trypsinized and reverse transfected
using RNAiMax (Life Technologies) with 50 μM of the
following siRNAs (Life Technologies): SPRY4-IT1 Stealth
RNAi 594, SPRY4 Exon 1 Custom Select siRNA, lipin 2
Silencer Select siRNAs s18590 and s18591, and Universal
Negative control (Cat #46-2001).
www.impactjournals.com/oncotarget
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Real-time qRT-PCR

Bioanalyzer prior to analysis by northern blotting.

Affinity Purification of Endogenous SPRY4-IT1

Quantitative PCR was carried out using
TaqMan mRNA or SYBR Green mRNA assays
with a 7500 Real-Time PCR System (Applied
Biosystems/Life Technologies), in accordance with
the manufacturer’s protocols. SDS1.2.3 software
(Applied Biosystems) was used for comparative Ct
analysis, with 18S rRNA serving as the endogenous
control. Primers for SYBR qPCR were as follows:
SPRY4-IT1 qPCR For, gctgagctggtggttgaaaggaatc;
SPRY4-IT1
qPCR
Rev,
gcttggcccacgatgacttgg;
SPRY4 Exon 1 qPCR For, ggcagtggttgcaacatcgccg;
SPRY4 Exon 1 qPCR Rev, tagccgccgctgtactcgcagac;
LPIN2 qPCR For, cgtctaagcagcccttctatgctgc; LPIN2
qPCR Rev, acatgctccacgagctcactcagc; LPIN1 qPCR
For, ggagagctggtacaggaacatgcaaag; LPIN1 qPCR
Rev, gcagtggctctctccaaaaggtgaag; GPAT3 qPCR
For,
caaggaggcctgactgaacttccc;
GPAT3
qPCR
Rev, ccgtcctcttagctgagagatccattg; DGAT1 qPCR
For, caacaaggacggagacgccgg; DGAT1 qPCR Rev,
gatgccacggtagttgctgaagcc;
DGAT2
qPCR
For,
ctgcactgattgctggctcatcg; and DGAT2 qPCR Rev,
gaaagtagcgccacacagcccag.

A375 cells (108 per sample) were grown to 8090% confluency, the medium was discarded, and the
plates were washed with PBS. The cells were trypsinized,
pelleted at low speed, washed with PBS, and resuspended
in 90 ml PBS (~106 cells/ml). Cells were crosslinked
by incubation in 1% formaldehyde at RT with rotation,
and then quenched by the addition of glycine to a
final concentration of 375 mM for 5 min. The cells
were centrifuged at low speed, washed in PBS, and
recentrifuged. The pellet was resuspended in Buffer A
(1% NP-40, 1 mM DTT), homogenized, and spun at low
speed. The pellet was resuspended in nuclei lysis buffer
(1 mM DTT, 1× protease inhibitor, and 2 μl RNaseOut)
at a volume of 1ml per 25 × 106 cell equivalents. The
lysate was incubated on ice, sonicated to yield 100-500 bp
fragments (Duty Cycle, 20%; intensity, 10; cycles/burst,
200; and time, 8 min), and then centrifuged at high speed.
The supernatant was removed and mixed with 0.5 M
LiCl2, then 500 pmol/25 × 106 cell equivalents of a SPRY4IT1 probe was added, and the sample was incubated at
37°C for 24 h. The probe consisted of a 25-bp sequence
complementary to SPRY4-IT1 constructed with a locked
nucleic acid (LNA) backbone and a 5′-biotin label. Control
samples contained probes complementary to the test probe
sequence. A 2 ml aliquot of streptavidin-coated Dynabeads
(Life Technologies) was washed twice with water and
once with hybridization buffer, and then blocked with 800
μg yeast tRNA and 800 μg BSA for 1 h at 37°C. The beads
were pelleted, washed twice in nuclear lysis buffer, and
resuspended in 2 ml of the same buffer. Prepared beads
were added to the nuclear lysate (125 μl per 500 pmol of
probe), rotated at 37°C, and then washed twice in 1 ml
nuclear lysis buffer and twice in 1 ml wash buffer (5 mM
Tris-HCl pH 7.5, 0.5 mM EDTA, 1M NaCl). Beads from
replicate samples were combined, washed twice in PBS,
resuspended in PBS, incubated at 75°C for 5 min, and
applied to a magnet. The isolated beads were incubated at
65°C overnight to reverse crosslinking, treated with 1 μg/
ml RNase A, vortexed, and incubated at RT. The samples
were then treated with proteinase K, resuspended in Buffer
AL, and incubated at 56°C. Finally, RNA in the complexes
was purified using the DNeasy Kit, eluted in RNase-free
H2O, and qRT-PCR was performed to quantify SPRY4-IT1.
The RNA-protein complexes were then subjected to LTQ
Orbitrap Velos MS for analysis of SPRY4-IT1–associated
proteins. Protein digestion, TiO2-based phosphopeptide
enrichment, and ESI-MS/MS was performed at the
proteomics core facility at Sanford-Burnham. Table S1
lists the identified SPRY4-IT1–binding proteins. RNA coimmunoprecipitation (RIP) was performed as previously
described [36]. Lipin-2 antibody H-160 was from Santa
Cruz (sc-134433).
www.impactjournals.com/oncotarget

RNA-FISH Analysis
RNA-FISH was performed using an LNAmodified probe for human SPRY4-IT1 (5′-Texas RedTCCACTGGGCATATTCTAAAA) and a RiboMap in
situ hybridization kit (Ventana Medical Systems, Inc.) on
a Ventana machine. SPRY4-IT1-EE and vector-only cells
were resuspended at 105 cells/ml, and 100 µl was added
to separate cloning rings on an autoclaved glass slide. The
following day, the rings were removed, and the slide was
washed in PBS and fixed in 4% paraformaldehyde and
5% acetic acid. After acid treatment using hydrochloridebased RiboClear reagent (Ventana Medical Systems) for
10 min at 37°C, the slide was treated with the ready-touse protease 3 reagent, and subjected to a denaturing prehybridization step for 4 min at 80°C. The cells were then
hybridized with 40 nM LNA-modified probe in RiboHybe
hybridization buffer (Ventana Medical Systems) for 2 h
at 58°C. The slide was washed 3 times for 4 min at 60°C;
once at low stringency with 0.1× SSC (Ventana Medical
Systems) and twice with 1× SSC. The slides were fixed
in RiboFix and counterstained with DAPI in an antifade
reagent (Ventana Medical Systems). Images were acquired
using a Nikon A1R VAAS laser confocal microscope.

5′ RACE for SPRY4-IT1
5′ RACE was performed using the FirstChoice®
RLM-RACE (RNA Ligase-Mediated RACE) kit
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(Ambion, Life Technologies). Total RNA was isolated
from A375 cells with TRIzol, and 1 μg per sample was
ligated to the 5′ RACE adapter using T4 RNA Ligase.
This sample was then reverse transcribed using M-MLV
reverse transcriptase. The samples were not treated with
either calf intestinal alkaline phosphatase or tobacco acid
pyrophosphatase and mRNA molecules thus retained both
the 5′ 7-methyl cap and the 5′ phosphate. Multiple reverse
primers were designed within the SPRY4-IT1 sequence to
complement the forward 5′ RLM-RACE primers. PCR
reactions were performed using Phusion polymerase
(Finnzymes), run out and purified from agarose gels, and
cloned into pCR4-TOPO (Life Technologies) for sequence
evaluation (Retrogen). The SPRY4-IT1 RACE product
was successfully acquired using the 5′ RACE inner
primer (supplied with the FirstChoice® kit) and 5′ RACE
SPRY4-IT1 reverse primer, residing 385 bp into SPRY4IT1 (ctctctggggacgatgcagcatccgatgg).

RNAs. Nucleic Acids Res. 2012; 40(14):6391-6400.
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